مباشر

FierceBiotechRoche nabs European approval for second Eli Lilly-partnered Alzheimer’s test FierceBiotechBayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drug BioPharma DiveA year after Vertex’s big launch, pain drug research faces a pivotal moment Endpoints NewsFlagship startup Serif says it has solved non-viral gene therapy in monkeys FierceBiotechBlood-based approach could detect early heart, kidney disease, study finds Endpoints NewsBristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B AgilentAgilent expands collaboration with C-CAMP to scale access to advanced life sciences analytics - BioSpectrum India FierceBiotechEnterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled LabiotechThe real reason CGT programs struggle to scale FierceBiotechBristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed eLifeScience under threat around the world eLifeFunctional imaging of nine distinct neuronal populations under a miniscope in freely behaving animals

FierceBiotech ١٢ مايو ٢٠٢٦

Enterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled

A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has hit its primary endpoint, furthering the biotech’s pursuit of a target that compa...

A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has hit its primary endpoint, furthering the biotech’s pursuit of a target that companies including Vertex have worked on previously.